Difference between revisions of "ICRP Glossary"
| Line 467: | Line 467: | ||
*[[Latent time/period or latency interval]] | *[[Latent time/period or latency interval]] | ||
| − | *[[LD<sub>50/30</sub>]] | + | *[[LD 50/30|LD<sub>50/30</sub>]] |
*[[Life Span Study]] | *[[Life Span Study]] | ||
| Line 498: | Line 498: | ||
=== <big><span id="M">M</span></big> === | === <big><span id="M">M</span></big> === | ||
| − | |||
*[[Macrophage colony stimulating factor]] | *[[Macrophage colony stimulating factor]] | ||
| Line 511: | Line 510: | ||
*[[Mitigation]] | *[[Mitigation]] | ||
| + | |||
| + | *[[Multiplicative risk projection model]] | ||
| + | |||
| + | *[[Multistage carcinogenesis model]] | ||
*[[Multistage tumorigenesis]] | *[[Multistage tumorigenesis]] | ||
| + | |||
| + | *[[Mutation component]] | ||
*[[Myocardial perfusion]] | *[[Myocardial perfusion]] | ||
| Line 527: | Line 532: | ||
*[[Neurovascular syndrome]] | *[[Neurovascular syndrome]] | ||
| + | |||
| + | *[[Nominal risk coefficient]] | ||
| + | |||
| + | *[[Non-homologous end joining]] | ||
*[[Non-maleficence]] | *[[Non-maleficence]] | ||
*[[Non-sphericity parameter]] | *[[Non-sphericity parameter]] | ||
| + | |||
| + | *[[Non-targeted effects]] | ||
| + | |||
| + | *[[Normal tissue complication probability]] | ||
*[[Nuclear track detectors]] | *[[Nuclear track detectors]] | ||
| Line 536: | Line 549: | ||
=== <big><span id="O">O</span></big> === | === <big><span id="O">O</span></big> === | ||
| + | *[[Occupational exposure]] | ||
| − | *[[ | + | *[[Oncogene]] |
*[[Optimisation]] | *[[Optimisation]] | ||
| Line 564: | Line 578: | ||
*[[Platelet-derived growth factor]] | *[[Platelet-derived growth factor]] | ||
| + | |||
| + | *[[Pooled analysis]] | ||
| + | |||
| + | *[[Population risk]] | ||
*[[Potential exposure]] | *[[Potential exposure]] | ||
| + | |||
| + | *[[Potentially lethal damage repair]] | ||
*[[Practical radiological protection culture]] | *[[Practical radiological protection culture]] | ||
| Line 597: | Line 617: | ||
=== <big><span id="Q">Q</span></big> === | === <big><span id="Q">Q</span></big> === | ||
| + | *[[Qualified expert]] | ||
| − | *[[ | + | *[[Quasi-threshold dose]] |
=== <big><span id="R">R</span></big> === | === <big><span id="R">R</span></big> === | ||
| Line 607: | Line 628: | ||
*[[Radiation modifier]] | *[[Radiation modifier]] | ||
| + | |||
| + | *[[Radiation risk]] | ||
*[[Radiation safety officer]] | *[[Radiation safety officer]] | ||
| Line 637: | Line 660: | ||
*[[Radiosensitivity, cellular]] | *[[Radiosensitivity, cellular]] | ||
| + | |||
| + | *[[Reactive oxygen species]] | ||
*[[Reasonableness]] | *[[Reasonableness]] | ||
| Line 643: | Line 668: | ||
*[[Recovery responder]] | *[[Recovery responder]] | ||
| + | |||
| + | *[[Recovery (cellular)]] | ||
| + | |||
| + | *[[Reference Animal and Plant]] | ||
*[[Reference bioassay function]] | *[[Reference bioassay function]] | ||
| Line 651: | Line 680: | ||
*[[Rehabilitation of living conditions]] | *[[Rehabilitation of living conditions]] | ||
| + | |||
| + | *[[Relative biological effectiveness]] | ||
| + | |||
| + | *[[Relative life lost]] | ||
| + | |||
| + | *[[Relative risk]] | ||
*[[Relocation]] | *[[Relocation]] | ||
| Line 679: | Line 714: | ||
*[[Rigidity]] | *[[Rigidity]] | ||
| + | |||
| + | *[[Ring chromosome]] | ||
| + | |||
| + | *[[Risk]] | ||
| + | |||
| + | *[[Risk coefficient]] | ||
| + | |||
| + | *[[Risk model]] | ||
| + | |||
| + | *[[Risk of exposure-induced death]] | ||
*[[Routine monitoring]] | *[[Routine monitoring]] | ||
| Line 693: | Line 738: | ||
*[[Senescence]] | *[[Senescence]] | ||
| + | |||
| + | *[[Severe deterministic injury]] | ||
*[[Slow repair]] | *[[Slow repair]] | ||
| Line 703: | Line 750: | ||
*[[Solar wind]] | *[[Solar wind]] | ||
| + | |||
| + | *[[Somatic effect]] | ||
*[[Source term]] | *[[Source term]] | ||
| Line 717: | Line 766: | ||
*[[Stenosis]] | *[[Stenosis]] | ||
| + | |||
| + | *[[Stochastic effect]] | ||
*[[Storage]] | *[[Storage]] | ||
*[[Subcutaneous tissue]] | *[[Subcutaneous tissue]] | ||
| + | |||
| + | *[[Sublethal damage repair]] | ||
*[[Substantial radiation dose level]] | *[[Substantial radiation dose level]] | ||
| Line 736: | Line 789: | ||
*[[Target tissue]] | *[[Target tissue]] | ||
| + | |||
| + | *[[Targeted effects]] | ||
*[[Telangiectasia]] | *[[Telangiectasia]] | ||
Revision as of 20:21, 24 February 2021
The ICRP Glossary collects ICRP’s definitive explanations of terms for current use. It is a living document, updated regularly. Each entry shows the date it was last updated, and some include past glossary entries to help readers better understand the term in a particular context.
Many ICRP publications have included their own glossaries. The ICRP Glossary includes most of the terms in these other glossaries, many with updated entries. ICRP publications will continue to have their own glossaries when necessary, for example for highly specialized terms relevant to a single publication or helpful for a reader to have close at hand, or when introducing a new term which would also be added to the ICRP Glossary.
Although the ICRP Glossary is not a dictionary, terms already well covered in the Oxford English Dictionary are not included here unless further explanation is needed to understand the way in which these terms are used in ICRP publications.
The ICRP Glossary shown here comprises some 400 terms. Entries for an additional approximately 400 terms are being prepared, and will be added here in due course.
| A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z |
